美国 · SEC FORM 4
Kymera Therapeutics, Inc.
KYMR · Nasdaq · CIK 0001815442 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
200 同一窗口内观察到的 Form 4 交易行
183 sales · 17 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-12-11 · 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP · $172.5M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出High
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Booth BruceDirector
○▼▼▼▼▼▼▼▼▼▼▼▼
Mainolfi NelloChief Executive Officer
○▼○▼○▼○▼
Goodman NoahChief Business Officer
○▼○▼▼
Jacobs Bruce N.Chief Financial Officer
○○○▼
Chadwick Jeremy GChief Operating Officer
▼▼▼
Ridloff ElenaDirector
○▼
● 买入▼ 卖出○ 其他
Showing the six most active owners; 4 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-12-11 · 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP.
近期 Form 4 活动
2买入
275卖出
48其他 Form 4 交易行
53SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出183 sale line(s) · 仅供背景
其他17 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 9,910,014
- 上期报告
- 10,530,809
- 日均成交量
- 828,028
- 回补天数
- 12.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-11 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 2,005,813 | USD 86.00 | USD 172,499,918 | SEC 申报 ↗ |
| 2025-06-30 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Stock, $0.0001 par value | 317,167 | USD 44.00 | USD 13,955,348 | SEC 申报 ↗ |
| 2025-06-30 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 655,500 | USD 44.00 | USD 28,842,000 | SEC 申报 ↗ |
| 2024-08-20 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 1 | USD 46.41 | USD 46 | SEC 申报 ↗ |
| 2023-11-03 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Stock, $0.0001 par value | 197,699 | USD 14.07 | USD 2,781,625 | SEC 申报 ↗ |
| 2023-11-02 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Stock, $0.0001 par value | 216,406 | USD 11.64 | USD 2,518,966 | SEC 申报 ↗ |
| 2023-01-12 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Stock, $0.0001 par value | 18,897 | USD 31.24 | USD 590,342 | SEC 申报 ↗ |
| 2023-01-11 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Stock, $0.0001 par value | 22,110 | USD 29.89 | USD 660,868 | SEC 申报 ↗ |
| 2022-08-22 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Stock, $0.0001 par value | 545,525 | USD 26.00 | USD 14,183,650 | SEC 申报 ↗ |
| 2022-05-27 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Stock, $0.0001 par value | 65,369 | USD 14.78 | USD 966,154 | SEC 申报 ↗ |
| 2022-05-26 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Stock, $0.0001 par value | 224,057 | USD 14.21 | USD 3,183,850 | SEC 申报 ↗ |
| 2022-05-20 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Stock, $0.0001 par value | 10,100 | USD 14.00 | USD 141,400 | SEC 申报 ↗ |
| 2022-05-06 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Stock, $0.0001 par value | 100,000 | USD 19.26 | USD 1,926,000 | SEC 申报 ↗ |
| 2022-05-05 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Stock, $0.0001 par value | 150,000 | USD 19.60 | USD 2,940,000 | SEC 申报 ↗ |
| 2022-01-31 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 买入 (P) | Common Stock, $0.0001 par value | 34,408 | USD 40.70 | USD 1,400,406 | SEC 申报 ↗ |
Form 4 申报证据
325 transaction lines in the latest 365-day window; 750 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Mainolfi Nello | 卖出 (S) | Common Stock | 30,000 | USD 113.80 | USD 3,413,917 | SEC 申报 ↗ |
| 2026-10-01 | Mainolfi Nello | 期权行权／转换 (M) | Common Stock | 30,000 | USD 2.08 | USD 62,400 | SEC 申报 ↗ |
| 2026-09-04 | Adams Brian | 卖出 (S) | Common Stock | 6,371 | USD 116.83 | USD 744,297 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Mainolfi Nello | 卖出 (S) | Common Stock | 30,000 | USD 113.80 | USD 3,413,917 | SEC 申报 ↗ |
| 2026-10-01 | Mainolfi Nello | 期权行权／转换 (M) | Common Stock | 30,000 | USD 2.08 | USD 62,400 | SEC 申报 ↗ |
| 2026-09-04 | Adams Brian | 卖出 (S) | Common Stock | 6,371 | USD 116.83 | USD 744,297 | SEC 申报 ↗ |
| 2026-07-27 | Rooney Terence | 奖励／授予 (A) | Common Stock | 38,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-07 | Mainolfi Nello | 卖出 (S) | Common Stock | 50,000 | USD 119.00 | USD 5,950,000 | SEC 申报 ↗ |
| 2026-07-07 | Mainolfi Nello | 期权行权／转换 (M) | Common Stock | 50,000 | USD 2.08 | USD 104,000 | SEC 申报 ↗ |
| 2026-07-01 | Mainolfi Nello | 卖出 (S) | Common Stock | 80,000 | USD 115.30 | USD 9,223,733 | SEC 申报 ↗ |
| 2026-07-01 | Mainolfi Nello | 期权行权／转换 (M) | Common Stock | 80,000 | USD 2.08 | USD 166,400 | SEC 申报 ↗ |
| 2026-07-01 | Goodman Noah | 卖出 (S) | Common Stock | 3,389 | USD 114.29 | USD 387,329 | SEC 申报 ↗ |
| 2026-06-30 | Jacobs Bruce N. | 卖出 (S) | Common Stock | 77,109 | USD 114.97 | USD 8,864,858 | SEC 申报 ↗ |
| 2026-06-30 | Jacobs Bruce N. | 期权行权／转换 (M) | Common Stock | 61,378 | USD 5.33 | USD 327,145 | SEC 申报 ↗ |
| 2026-06-29 | Booth Bruce | 卖出 (S) | Common Stock | 76,650 | USD 108.05 | USD 8,281,905 | SEC 申报 ↗ |
| 2026-06-29 | Booth Bruce | 卖出 (S) | Common Stock | 31,283 | USD 109.48 | USD 3,424,800 | SEC 申报 ↗ |
| 2026-06-29 | Booth Bruce | 卖出 (S) | Common Stock | 45,367 | USD 107.06 | USD 4,857,104 | SEC 申报 ↗ |
| 2026-06-26 | Booth Bruce | 卖出 (S) | Common Stock | 467,878 | USD 110.29 | USD 51,603,032 | SEC 申报 ↗ |
| 2026-06-26 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | 卖出 (S) | Common Stock, $0.0001 par value | 1,630,658 | USD 106.50 | USD 173,665,077 | SEC 申报 ↗ |
| 2026-06-25 | Goodman Noah | 卖出 (S) | Common Stock | 5,000 | USD 114.00 | USD 570,000 | SEC 申报 ↗ |
| 2026-06-25 | Goodman Noah | 期权行权／转换 (M) | Common Stock | 5,000 | USD 21.05 | USD 105,250 | SEC 申报 ↗ |
| 2026-06-25 | Booth Bruce | 卖出 (S) | Common Stock | 285,684 | USD 121.86 | USD 34,812,909 | SEC 申报 ↗ |
| 2026-06-25 | Booth Bruce | 卖出 (S) | Common Stock | 262,637 | USD 115.39 | USD 30,306,107 | SEC 申报 ↗ |
| 2026-06-24 | Booth Bruce | 卖出 (S) | Common Stock | 134,720 | USD 100.51 | USD 13,540,476 | SEC 申报 ↗ |
| 2026-06-23 | Booth Bruce | 卖出 (S) | Common Stock | 1,408 | USD 99.98 | USD 140,772 | SEC 申报 ↗ |
| 2026-06-22 | Goodman Noah | 卖出 (S) | Common Stock | 2,500 | USD 99.00 | USD 247,500 | SEC 申报 ↗ |
| 2026-06-22 | Goodman Noah | 期权行权／转换 (M) | Common Stock | 2,500 | USD 21.05 | USD 52,625 | SEC 申报 ↗ |
| 2026-06-22 | Booth Bruce | 卖出 (S) | Common Stock | 31,798 | USD 103.75 | USD 3,299,037 | SEC 申报 ↗ |
| 2026-06-22 | Booth Bruce | 卖出 (S) | Common Stock | 246,330 | USD 98.52 | USD 24,268,861 | SEC 申报 ↗ |
| 2026-06-18 | Booth Bruce | 卖出 (S) | Common Stock | 115,056 | USD 91.01 | USD 10,471,661 | SEC 申报 ↗ |
| 2026-06-17 | Booth Bruce | 卖出 (S) | Common Stock | 116,812 | USD 90.34 | USD 10,552,772 | SEC 申报 ↗ |
| 2026-06-17 | Booth Bruce | 期权行权／转换 (M) | Common Stock | 11,741 | USD 20.00 | USD 234,820 | SEC 申报 ↗ |
| 2026-06-02 | Jacobs Bruce N. | 期权行权／转换 (M) | Common Stock | 12,653 | USD 2.08 | USD 26,318 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | KYMR |
| CIK | 0001815442 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 750 transaction lines from 2020-08-21 to 2026-10-01 45 P purchase lines · 528 S sale lines · 177 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.